ClinicalTrials.gg
Not yet recruitingNCT07920575ATLASUpdated Nov 5, 2026

Assessment of Transnational Performance of the Universal Cardiac Surgical Risk Score Across International Sites

An observational study in Heart Valve Diseases, Cardiac Surgical Procedures and Coronary Artery Disease, sponsored by Union Health System. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Union Health System · Observational

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Study summary

ATLAS is a prospective, observational, multicenter cohort study of how accurately the Universal Cardiac Surgical Risk Score (UCSRS) predicts 30-day outcomes after adult cardiac surgery, compared head-to-head with two established models, STS-PROM and EuroSCORE II. Consecutive adult patients undergoing cardiac surgery are enrolled at each participating center over 12 months. All three scores are recorded for each patient. No score is returned to the treating team or influences clinical care. Discrimination and calibration of each score are assessed against 30-day major adverse cardiac and cerebrovascular events (MACCE). The model under evaluation, UCSRS version 3.2, was specified and calibrated against published registry mortality using simulated patients before enrollment. No simulated patient has an outcome, so no performance claim is made before this study.

Read the detailed description

DATA AND ANALYSIS Each site records the clinical variables from which the scores are computed, the site's own STS-PROM and EuroSCORE II values (comparators only; they never enter the UCSRS score), the Frailty Test components, and the 30-day outcome components. Sites compute no derived quantities; every derived value is computed centrally by the same code.

Data are de-identified at the site. A site either sends a de-identified patient-level dataset to the coordinating center or runs the identical standardized analysis locally and shares only summary results (c-statistic, observed/expected ratio, calibration slope and intercept), which are combined by summary-level meta-analysis. Discrimination uses the c-statistic with the DeLong test; calibration uses calibration plots, the observed/expected ratio, and calibration slope and intercept.

MODEL UNDER EVALUATION UCSRS version 3.2 (specification 3.2.0) has a single log-odds baseline computed from the patient's own clinical variables, to which it adds a required frailty correction (Frailty Test, 0-6: chair-rise, cognition assessment, hemoglobin, albumin) and optional corrections for liver function (MELD), left ventricular geometry and coronary complexity (SYNTAX), and right-heart catheterization. STS-PROM and EuroSCORE II are calculated independently by each site on the official calculators and are used only as comparators.

VERSION HISTORY Version 1.0 was published (J Cardiothorac Surg 2026; DOI 10.1186/s13019-026-04433-x), with a baseline blending STS-PROM and EuroSCORE II. Version 2.0 (27 August 2026) removed STS-PROM from the baseline. Version 2.1 (28 August 2026) rebuilt the baseline in log-odds. Version 3.0 replaced the blend with a single logistic baseline from which EuroSCORE II was removed entirely. Version 3.1 (20 September 2026) reset the calibration constant. Version 3.2 (24 October 2026) counted aortic disease once, lowered the MELD slopes, applied the frailty ladder to the odds, added CABG + AVR + MVR as an operation, and re-solved the calibration constant. Each change is recorded in a dated specification of record. The protocol registered here is ATLAS Study Protocol version 4.3 (24 October 2026), which describes UCSRS version 3.2.

SIMULATION AND CALIBRATION The calibration constants were set before enrollment against published mortality from thirteen surgical registries. For each registry, a synthetic cohort was tuned until its mean EuroSCORE II matched that registry's published observed mortality divided by its published EuroSCORE II observed/expected ratio; this is the only point at which real-world information enters. Runs scored millions of synthetic patients: about 11 million exploratory simulations in version 2.1 (which set no constant); 30,000,000-patient runs across the 13 registry-anchored cohorts in versions 3.0 and 3.1; and, in version 3.2, a 325,000-patient solve, a 520,000-patient hold-out, a 29,999,996-patient locking run and two 2,600,000-patient hold-outs. At the version 3.2 constant the median observed/expected ratio across the 13 registries was 1.0011 in the locking run, with hold-outs of 0.9968 and 0.9936. A separate 1,000,000-patient high-risk validation lowered mean predicted risk from 52.3% (version 3.1) to 20.8% (version 3.2) and the share of patients at the 70% score cap from 40.1% to 0.003%.

STRUCTURAL ENUMERATION On 15 September 2026 a complete factorial enumeration of 318,162,816 input combinations (cells, not patients) was run on a development version of the scoring engine, with a provisional intercept and no calibration shift. It covered elective first-time and redo operations and all eleven procedure codes on a deliberately adverse grid (MELD of 10 or more, hemoglobin 13 g/dL or less, albumin 4.0 g/dL or less). It was used to examine structure only: relative behavior, ordering, dynamic range and saturation at the score cap. Its absolute values are uncalibrated and are not risk estimates. In this grid EuroSCORE II, which carries a single flag for previous cardiac surgery and a single flag for thoracic aortic disease, separated a second redo sternotomy from a first redo by 0.02 percentage points and separated aortic root and arch operations from ascending replacement by 0.18 points; the UCSRS engine distinguished these operations. The results are recorded in a dated results document.

LIMITS OF THE SIMULATIONS No simulated patient has an outcome, and no outcome model was used at any stage. Discrimination therefore cannot be assessed in simulation, and the calibration results show internal consistency, not superiority over STS-PROM or EuroSCORE II. No performance claim accompanies the current specification. The version 3.2 constants were set by the investigator before first enrollment, as a documented exception to an earlier commitment; they are not moved again before 5,000 patients are enrolled.

The coordinating investigator developed UCSRS. This is declared in all study documents and publications, and negative results will be published.

02

Conditions studied

  • Heart Valve Diseases
  • Cardiac Surgical Procedures
  • Coronary Artery Disease

Keywords

  • cardiac surgery
  • risk score
  • risk prediction
  • operative mortality
  • STS-PROM
  • Euro Score II
  • Calibration
  • Frailty
  • MACCE
03

In context

Heart Valve Diseases

552 studies on the registry are indexed under Heart Valve Diseases; 162 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 300 across 226 observational studies indexed under Heart Valve Diseases.

Browse Heart Valve Diseases studies →

Lead sponsor

This is the only study on the registry with Union Health System as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive adult patients undergoing cardiac surgery at each participating center, enrolled over a 12-month period

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Undergoing cardiac surgery at a participating institution during its enrollment period (isolated CABG, isolated valve, combined CABG and valve, multiple valve, aortic surgery, redo sternotomy, or other adult cardiac surgical procedures, on- or off-pump)
  • Enrolled consecutively, without selection

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years
  • Congenital heart surgery performed under a pediatric program
  • Heart transplantation or ventricular assist device implantation as the primary procedure
  • Cases in which the comparator scores cannot be computed from available pre-operative data
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult cardiac surgery patients

    Consecutive patients 18 years or older undergoing cardiac surgery at a participating site. Risk scores are calculated for research only and do not change care

    Other: Risk score calculation

Interventions

  • OtherRisk score calculation

    Calculation of UCSRS, STS-PROM and EuroSCORE II risk scores from pre-operative data, for assessment of discrimination and calibration against observed 30-day outcomes. UCSRS coefficients are fixed and version-locked. No effect on clinical care

06

What researchers measure

Primary outcomes

  1. 30 day MACCE

    Occurrence within 30 days after surgery of any component of a composite of all-cause mortality, permanent stroke, renal failure (per the current STS Adult Cardiac Surgery Database definition) and prolonged ventilation (more than 24 hours). STS standard definitions are applied at all sites. Used to assess discrimination and calibration of UCSRS, STS-PROM and EuroSCORE II.

    Time frame: 30 days after surgery

  2. 30 day all cause mortality

    Death from any cause within 30 days of the index procedure, or in-hospital death after day 30 where the patient has remained continuously admitted since the index procedure. Used to assess calibration (observed/expected ratio, calibration slope and intercept) of UCSRS, STS-PROM and EuroSCORE II.

    Time frame: 30 day after surgery

Secondary outcomes

  1. Reoperation

    Reoperation for any cause within 30 days after surgery (STS definition)

    Time frame: 30 days after surgery

  2. Number of Participants with Deep Sternal Wound Infection

    Deep Sternal wound infection within 30 days of surgery (STS definition)

    Time frame: 30 days after surgery

  3. Number of Participants with Major Bleeding

    Major bleeding within 30 days of surgery (STS definition)

    Time frame: 30 days after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Universal cardiac surgical risk score (UCSRS v1.0) a unified physiology-informed risk architecture for operative mortality prediction across all adult cardiac surgical procedures: algorithm design and prospective validation protocol; J Cardiothoracic Surgery, Accepted in July 2026; (In-Press) DOI: 10.1186/s13019-026-04433

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared. The coordinating center holds pooled data made up of de-identified patient-level data from sites that choose to share it and summary results from sites that analyze locally. These are held under site data use agreements and local ethics approvals that do not permit onward sharing. Aggregate results will be published

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07920575
Lead sponsor
Union Health System
Responsible party
Sponsor
First posted
Nov 5, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Atiq Rehman, MD
Contact
atiqmd@aol.com
(609)304-8397
Atiq Rehman, MD
principal investigator · Union Health System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion